drugset / Trial / NCT01279876

Melatonin in Relapsing-Remitting Multiple Sclerosis Patients

NCT01279876

Phase 2 Completed 25 enrolled Tehran University of Medical Sciences
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether melatonin is effective in the treatment of relapsing-remitting multiple sclerosis patients as a supplement to the main disease-modifying drugs.

Timeline

Start
2010-10
Primary completion
2014-01
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Melatonin Small molecule 3 mg Oral